This report provides a comprehensive review of nanotechnology and it’s role in the development of next-generation nanomedicines.

Microdosing (Phase 0 Trials), adaptive trials, phase IV trials and the role of information technology

Visiongain predict that the current phase I to IV clinical testing process will eventually be selectively or wholly replaced by a system known as "in-life" testing or "live" licensing.

This brief offers an analysis of the industry environment for translational medicine..

Executive Presentations, delivered in a concise presentation format, enable our clients to access and share the content of our ongoing Pharmaceutical Technology Research Stream quickly and efficiently. This is an executive summary delivered in a presen

The purpose of this report is to describe the specific market segments of the medical research space using stem cells for research and development (R&D) purposes.

a new report that provides in-depth analysis of leading pharma companies that are using novel technologies to reposition failed, marketed or reformulated compounds.

Waves of technological advancements have powered significant evolution in R&D from serendipitous drug discovery, through to rational drug design. However, as the low-hanging fruit has been picked, and recent technological advances have failed to yield

Comprehensive analysis of the shift towards translational medicinein the pharmaceutical industry, key enabling technologies and vendor requirements.

A global analytical guide and comparative analysis of international destinations, with location attractiveness index

This report explores the benefits that pharmaceutical companies can gain from using online solutions to accelerate the R&D process.

This report assesses the role of targeted cancer therapies as a driver of growth in the cancer market and their future role potential.

A complete and systematic description of the past, present and future efforts in cancer R&D focused on the vascular targeting field.

In this Analytical Tool, BioSeeker Group brings light and understanding of the whole industrial endeavor in apoptosis as cancer therapeutic target.

The ultimate tool for serious players who would like to understand the current competitive field in cancer drug development among anti-angiogenic and vascular targeting agents.

There are today more than 250 therapeutics targeting colorectal cancer, from early preclinical to marketed drugs. Colorectal Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 134

There are today more than 340 therapeutics targeting breast cancer, from early preclinical to marketed drugs. Breast Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 165 d

An update on the most recent advances made for vascular targeting agents that are now entering an exciting stage of development.

Melanoma drug development has and will continue to have a strong focus on target therapy such as vaccines, monoclonal antibodies, dendritic cells, and gene therapy.

The ultimate tool for serious players who would like to understand the current competitive field in breast cancer drug development.

In this publication, BioSeeker Group analyzes the latest progress made for 25 drug candidates targeting the cell death pathway, apoptosis. Additionally, more early stage candidates are also under investigation, which brings the total number of compani

Gain insight into the current challenges and commercial opportunities associated with breast cancer therapy.

A unique tool for analyzing the complex competitive pressure within the different fields of leukemia therapeutics.

Overview of the most common fungal diseases, already marketed antifungal agents, details from recent studies on approved agents, and information on the recent activities of companies with developmental antifungals.

This analysis deals with 26 of the most promising pharmaceutical companies with anti-viral drugs on the market. Indication by indication is measured by number of current therapies, present sales and sales development.

BioSeeker Group analyzes the progress made by the large pharmaceutical companies top oncology drug candidates whom has reached Phase III clinical evaluation.

A fresh look on both the current world status of R&D and business development in HCV. Our research and analysis is built on more than 150 companies from over 18 different countries and include more than 160 pipline drugs in development for HCV.

A unique tool for analyzing the vast amount of strategic possibilities that have emerged in lymphoma R&D.

This CD-ROM product is one of the most comprehensive and up to date information sources on chronic hepatitis C virus R&D and business development.

Colorectal cancer (CRC) is the second most common cause of cancer death in much of the developed world. Cancer-related mortality is slowly decreasing as a result of better detection and significant advances in the treatment of advanced colorectal cance